April 13, 2021

Once patients stop responding to platinum-based chemotherapy for locally advanced or metastatic urothelial cancer, their treatment options had been somewhat limited: PD-1/PD-L1 inhibitors were effective in only 13%–29% of patients and taxanes in only 11%–13%. When the antibody drug conjugate enfortumab vedotin was approved in late 2019, it offered new hope for patients and providers, with clinical trials reporting a 44% objective response rate.

April 09, 2021

Tyrone is a 74-year-old man with a history of acute myeloid leukemia (AML), type 2 diabetes, and hypertension who was admitted to the hospital after lab results revealed 40% circulating blasts in his peripheral blood that was concerning for relapsed disease. He was diagnosed with AML three years ago and achieved remission after treatment with a hypomethylating agent. 

April 08, 2021

Despite accounting for only 3% of all cancer survivors, patients with head and neck cancers often require significant support and survivorship care. And oncology nurses can expect survivorship to grow with recent improvements in prognosis and treatment options, such as with reductions in human papillomavirus-related oropharyngeal cancers, which tend to affect young people and offer improved long-term survival rates.

April 07, 2021

Although society has tried to take steps to confront gender disparities, women remain underrepresented across various sectors. Title IX in 1972 granted every American student the right to education without gender discrimination. However, female students still bear the brunt of sex-segregated programs and gender-based violence, two major obstacles to educational equality. Women consistently earn less than their male counterparts. The wage gap is larger for most women of color, and gender discrimination and sexual harassment in the workplace perpetuate economic divides.